Cost-effectiveness of erlotinib vs. docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC)

7664 Background: Multiple treatment strategies are now available for stage IIIB/IV non-small cell lung cancer (NSCLC) after failure of 1st line treatment, but their relative economic and clinical v...